Celadon Pharmaceuticals

About Celadon

Founded in 2018, Celadon is a UK based pharmaceutical company with a primary focus of growing indoor hydroponic high quality cannabis initially for use within the chronic pain market. Celadon also aims to conduct research into cannabinoids for use in chronic pain and other conditions such as autism and multiple sclerosis, within the highly regulated UK market.

Celadon is in the advanced stages of the application process to receive licences from the Home Office and MHRA and therefore we expect to be one of the first businesses licenced under the new 2018 UK legislation to be able to grow and supply medicinal cannabis with a high tetrahydrocannabinol (THC) content in the UK, allowing us an opportunity to become the dominant player in what is expected to be a large and fast-growing UK market.

About Celadon

Founded in 2018, Celadon is a UK based pharmaceutical company with a primary focus of growing indoor hydroponic high quality cannabis initially for use within the chronic pain market. Celadon also aims to conduct research into cannabinoids for use in chronic pain and other conditions such as autism and multiple sclerosis, within the highly regulated UK market.

 

Celadon is in the advanced stages of the application process to receive licences from the Home Office and MHRA and therefore we expect to be one of the first businesses licenced under the new 2018 UK legislation to be able to grow and supply medicinal cannabis with a high tetrahydrocannabinol (THC) content in the UK, allowing us an opportunity to become the dominant player in what is expected to be a large and fast-growing UK market.